Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renoprotective effects of dapagliflozin in non-diabetic patients with proteinuria
2017-001090-16Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in 24-hour proteinuria. Started Jul 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2017-001090-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001090-16.